摘要
目的观察盐酸非索非那定联合桂利嗪及脾氨肽冻干粉治疗慢性荨麻疹的疗效。方法回顾性分析100例慢性荨麻疹患者的临床资料,依据用药方法不同分为联合用药组和单独用药组,各50例。单独用药组口服盐酸非索非那定片治疗,联合用药组在单独用药组基础上同时口服桂利嗪及脾氨肽冻干粉治疗。随访3个月,比较两组患者用药前后症状评分、皮肤病生活质量指数(DLQI)评分,血清细胞因子[γ干扰素(IFN-γ)、白三烯(LT)、一氧化氮(NO)、白细胞介素(IL)-2、IL-4、IL-10、IL-18]、免疫功能[免疫球蛋白(Ig)A、IgE、IgG、IgM]水平,临床疗效,不良反应发生情况,复发情况。结果用药后,两组患者风团数目评分、风团大小评分、风团持续时间评分、瘙痒程度评分、症状总分、DLQI评分均低于用药前,且联合用药组风团数目评分(0.36±0.11)分、风团大小评分(0.44±0.12)分、风团持续时间评分(0.48±0.15)分、瘙痒程度评分(1.27±0.11)分、症状总分(2.55±0.80)分、DLQI评分(5.40±1.26)分均低于单独用药组(1.32±0.25)、(1.36±0.25)、(1.85±0.36)、(1.36±0.22)、(5.89±1.12)、(7.63±1.38)分,差异显著(P<0.05)。用药后,两组患者血清LT、NO、IL-4、IL-10、IgE水平均低于用药前,血清IFN-γ、IL-2、IL-18、IgA、IgG、IgM水平均高于用药前,且联合用药组患者血清LT(60.51±10.27)pg/ml、NO(49.51±7.11)μmol/L、IL-4(3.01±0.51)ng/L、IL-10(4.48±0.67)ng/L、IgE(33.20±6.94)IU/ml均低于单独用药组的(84.21±10.80)pg/ml、(58.66±8.48)μmol/L、(4.41±0.77)ng/L、(6.85±0.93)ng/L、(45.60±7.70)IU/ml,血清IFN-γ(28.93±4.57)ng/L、IL-2(55.51±8.92)ng/L、IL-18(47.97±7.97)ng/L、IgA(0.97±0.13)g/L、IgG(7.71±0.37)g/L、IgM(1.66±0.20)g/L均高于单独用药组的(22.11±4.28)ng/L、(40.37±7.85)ng/L、(32.55±5.22)ng/L、(0.79±0.11)g/L、(7.55±0.31)g/L、(1.50±0.20)g/L,差异显著(P<0.05)。联合用药组临床总有效率98.00%(49/50)高于单独用药组的84.0
Objective To observe the efficacy of fexofenadine hydrochloride combined with cinnarizine and spleen aminopeptide lyophilized powder on chronic urticaria.Methods The clinical data of 100 patients with chronic urticaria were retrospectively analyzed and divided into combined medication group and single medication group according to different medication methods,with 50 cases in each group.The single medication group was treated with fexofenadine hydrochloride alone,and the combined medication group was treated with fexofenadine hydrochloride combined with cinnarizine and spleen aminopeptide lyophilized powder.After 3 months of follow-up,comparison was made on symptom score,dermatology life quality index(DLQI)score,and serum cytokine[interferon-γ(IFN-γ),leukotriene(LT),carbon monoxide(NO),interleukin-2(IL-2),IL-4,IL-10,IL-18],immune function[immunoglobulin(Ig)A,IgE,IgG,IgM]before and after medication,clinical efficacy,incidence of adverse reactions,and recurrence between the two groups.Results After medication,the wheal number score,wheal size score,wheal duration score,itching severity score,total symptom score and DLQI score in both groups were lower than those before medication;in the combined treatment group,the wheal number score was(0.36±0.11)points,the wheal size score was(0.44±0.12)points,the wheal duration score was(0.48±0.15)points,the itching severity score was(1.27±0.11)points,the total symptom score was(2.55±0.80)points,and the DLQI score was(5.40±1.26)points,which were lower than(1.32±0.25),(1.36±0.25),(1.85±0.36),(1.36±0.22),(5.89±1.12),and(7.63±1.38)points in the single medication group;the difference was significant(P<0.05).After treatment,the serum levels of LT,NO,IL-4,IL-10 and IgE in both groups were lower than those before treatment,and the serum levels of IFN-γ,IL-2,IL-18,IgA,IgG and IgM were higher than those before treatment;the combined medication group had serum LT of(60.51±10.27)pg/ml,NO of(49.51±7.11)μmol/L,IL-4 of(3.01±0.51)ng/L,IL-10 of(4.48±0.67)ng/L and IgE of(33.2
作者
刘伟
LIU Wei(Department of Dermatology,Juye County People's Hospital,Heze 274900,China)
出处
《中国现代药物应用》
2024年第12期37-41,共5页
Chinese Journal of Modern Drug Application
关键词
慢性荨麻疹
盐酸非索非那定
桂利嗪
脾氨肽冻干粉
不良反应
复发
Chronic urticaria
Fexofenadine hydrochloride
Cinnarizine
Spleen aminopeptide lyophilized powder
Adverse reactions
Recrudescence
